48 results
Thumbnail

000594 - The Role of Asthma and COVID-19 in Shaping the Severity of Pediatric Mycoplasma pneumoniae Infections: A Regional Perspective from the United States

Thumbnail

001503 - Urticaria exacerbations in children with chronic urticaria receiving COVID-19 vaccination

Thumbnail

- D3.100 - Risk Factors and Biomarkers for COVID-19 and Allergic Diseases

Thumbnail

- D3.115 - Outcome and complications of COVID-19 among children with asthma in South Korea: a national incident cohort study

Thumbnail

D3.273 - Assessing Anaphylaxis in COVID-19 vaccines: Application of amended Brighton Collaboration Criteria

Thumbnail

D3.378 - Long Covid in epithelial barrier type2 disease: an Italian experience

Thumbnail

D1.108 - Grape polyphenols increase the concentration of BPI in asthma patients who have had SARS-CoV-2

Thumbnail

D1.276 - Social #anaphylaxis: how social media reveals shifting trends in public health concerns

Thumbnail

D1.423 - Listening to Urticaria Patients Through Social Media: Analyzing the Impact of the COVID-19 Pandemic

Thumbnail

D1.424 - Clinical-epidemiological profile of patients with Post-Covid syndrome followed at a medical school outpatient clinic

Thumbnail

D1.426 - Cellular immunity profile in patients with urolithiasis in the presence of post-Covid syndrome

Thumbnail

000766 - Clonal mast cell disorders, allergy to hymenoptera venom and venom immunotherapy – our experience

Thumbnail

D1.231 - When Antihistamines Paradoxically Worsen Chronic Spontaneous Urticaria: Trust Your Patient

Thumbnail

- D3.117 - Targeting Mast Cells with Briquilimab, an Anti-Human c-Kit (CD117) Antibody, Mitigates COPD-Like Features in an Allergen and Cigarette Smoke-Exacerbated Asthma Model Using Humanized h/mCD117 Mice

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.204 - Elevated Tryptase Levels in a Severe Asthmatic Patient Undergoing SCIT for Birch: Implications for Monitoring and Personalized Treatment

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis